Word

SYNENDOS

Status

Registered

Status Code

700

Status Date

Tuesday, August 22, 2023

Serial Number

79330074

Registration Number

7141186

Registration Date

Tuesday, August 22, 2023

Mark Type

4000

Filing Date

Wednesday, November 10, 2021

Published for Opposition

Tuesday, June 6, 2023

Trademark Owner History

Synendos Therapeutics AG - Original Registrant

Classifications

5 Pharmaceutical products for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; pharmaceutical products for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medical preparations and substances for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; medical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; veterinary preparations and substances for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; veterinary preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; sanitary preparations for medical use; medicines for pharmaceutical use for the treatment of neuropsychiatric, neurological and psychiatric diseases and disorders; medicines for pharmaceutical use for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medicines for human medicine for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, renal, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, inflammatory, immune, autoimmune, and genetic diseases and disorders; medicines for human medicine, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; medicines for human medicine, namely, medicines for treating biochemical imbalances in vivo; chemical-pharmaceutical preparations, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for pharmaceutical use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for veterinary use, namely, pharmaceutical preparations acting on the central nervous system, biopharmaceutical preparations acting on the central nervous system, pharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use for treating biochemical imbalances in vivo; chemical preparations for veterinary use for treating biochemical imbalances in vivo; diagnostic substances, preparations and agents for medical use

44 Medical services; veterinary services; hygienic care for human beings; medical and pharmaceutical consultancy services; medical tests for diagnostic or treatment purposes; conducting of medical examinations; consultations regarding pharmacology; pharmaceutical consulting, namely, consultant and information services relating to pharmaceutical products; conducting of chemical, medical and biological analyses for medical diagnosis being medical diagnostic testing services; consultancy and information services relating to medical products being pharmaceutical consultation services; medical analysis services relating to the treatment of patients; medical consultancy services; pharmacy advice being pharmaceutical consultation

42 Scientific and technological services, namely, scientific research, analysis, testing in the fields of pharmaceuticals, biopharmaceuticals, chemistry, biology, biochemistry; industrial analysis services, namely, industrial analysis in the fields of pharmaceuticals, biopharmaceuticals; industrial research services in the fields of pharmaceuticals, biopharmaceuticals; scientific research and development; scientific research; scientific analysis, namely, biological analysis, biochemical analysis, chemical analysis; conducting chemical and biological analyses for scientific purposes; conducting medical analysis for scientific purposes, namely, biological analysis, biochemical analysis, chemical analysis, blood analysis; medical research; pharmaceutical research; research in the fields of chemistry and biology; biotechnological research services; providing medical and scientific research information, namely, providing information and data with respect to medical and veterinary research and development; providing information with respect to medical and scientific research in the field of pharmaceutical products; providing scientific information on research in the field of pharmaceutical products and biomedicine

Trademark Events

Feb 26, 2024

Teas Change Of Correspondence Received

Feb 26, 2024

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 26, 2024

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Feb 26, 2024

Applicant/Correspondence Changes (Non-Responsive) Entered

Feb 26, 2024

Teas Change Of Owner Address Received

Dec 11, 2023

Final Decision Transaction Processed By Ib

Nov 22, 2023

Final Disposition Notice Sent To Ib

Nov 22, 2023

Final Disposition Processed

Nov 22, 2023

Final Disposition Notice Created, To Be Sent To Ib

Aug 22, 2023

Notice Of Registration Confirmation Emailed

Aug 22, 2023

Registered-Principal Register

Jun 18, 2023

Notification Of Possible Opposition - Processed By Ib

Jun 6, 2023

Notification Processed By Ib

Jun 6, 2023

Official Gazette Publication Confirmation E-Mailed

Jun 6, 2023

Published For Opposition

May 31, 2023

Notification Of Possible Opposition Sent To Ib

May 31, 2023

Notification Of Possible Opposition Created, To Be Sent To Ib

May 17, 2023

Notification Of Possible Opposition Sent To Ib

May 17, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

May 17, 2023

Notification Of Notice Of Publication E-Mailed

May 6, 2023

Change Of Name/Address Rec'd From Ib

May 1, 2023

Approved For Pub - Principal Register

May 1, 2023

Examiner's Amendment Entered

May 1, 2023

Notification Of Examiners Amendment E-Mailed

May 1, 2023

Examiners Amendment E-Mailed

May 1, 2023

Examiners Amendment -Written

Mar 30, 2023

Teas/Email Correspondence Entered

Mar 30, 2023

Correspondence Received In Law Office

Mar 30, 2023

Teas Response To Office Action Received

Oct 25, 2022

Refusal Processed By Ib

Oct 1, 2022

Non-Final Action Mailed - Refusal Sent To Ib

Oct 1, 2022

Refusal Processed By Mpu

Aug 25, 2022

Non-Final Action (Ib Refusal) Prepared For Review

Aug 24, 2022

Non-Final Action Written

Aug 22, 2022

Assigned To Examiner

Jan 8, 2022

Application Filing Receipt Mailed

Jan 4, 2022

New Application Office Supplied Data Entered

Dec 30, 2021

Sn Assigned For Sect 66a Appl From Ib